Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

This is an exploratory study evaluating the efficacy and safety of neoadjuvant therapy with fulzerasib sequentially combined with sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small cell lung cancer (NSCLC) harboring KRAS G12C mutation. Approximately 30 treatment-naïve patients with stage IB-IIIA (AJCC 8th edition) NSCLC and confirmed KRAS G12C mutation will be enrolled. Eligible subjects will receive 6 weeks of fulzerasib followed by a 2-week washout period, then 3 cycles (q3w) of sintilimab plus investigator's choice of platinum-doublet chemotherapy. An end

Trial Details

NCT ID
NCT07492342
Phase
PHASE2
Sponsor
Jianxing He
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • fulzerasib
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Guangzhou, China|23.11667,113.25
  • Zhejiang, China|25.3238,105.583

Key Eligibility Criteria

  • Sign the Informed Consent Form (ICF) and be able to comply with the visit and related procedures as stipulated in the protocol.
  • Be male or female, aged ≥18 years old.
  • Histologically or cytologically confirmed primary non-small cell lung cancer (NSCLC).
  • Clinical stage IB to IIIA disease, according to the 8th edition of the TNM classification for lung cancer as defined by the International Associati…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →